Can ponatinib help if my chronic myeloid leukemia is resistant to other drugs?

If your chronic myeloid leukemia (CML) has stopped responding to other tyrosine kinase inhibitors (TKIs), ponatinib is a third-generation TKI that may still work. It is designed to target many resistant forms of CML, including those with the T315I mutation, which other drugs cannot treat. However, ponatinib comes with significant risks, especially cardiovascular side effects, so it is important to discuss these with your doctor.

What the research says

Ponatinib is a potent oral drug that blocks the BCR-ABL1 protein, even in its mutated forms. In the long-term PACE trial, 60% of heavily pretreated patients achieved a major cytogenetic response and 40% achieved a major molecular response; 5-year overall survival was 73% ¹⁰. A phase 2 study is testing different starting doses (45 mg, 30 mg, and 15 mg daily) in patients resistant to prior TKIs or with the T315I mutation, measuring molecular response at 12 months ⁵. However, cardiovascular adverse events are a major concern, and doctors often start with a higher dose and then reduce to 15 mg once the leukemia is under control ¹⁰. If ponatinib is not suitable, alternatives like asciminib or olverembatinib may be options ⁹¹⁰. Asciminib, an allosteric inhibitor, has shown activity in patients who failed multiple TKIs, including those with T315I ⁸. Olverembatinib, a third-generation TKI approved in China, also covers the T315I mutation and compound mutations ⁹.

What to ask your doctor

• What is my BCR-ABL1 mutation status, and does it include the T315I mutation?
• What dose of ponatinib would you recommend for me, and how will we monitor for side effects?
• What are my risks for cardiovascular problems, and how will we manage them?
• If ponatinib is not right for me, would asciminib or another newer TKI be an option?
• How often will I need blood tests to check if the drug is working?